Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenwei A Yayranji Pian is a traditional Uygur medicine developed by Xinjiang Uygur Pharmaceutical Co., Ltd. for the treatment of constipation. It is formulated as a tablet and is intended to improve bowel movement frequency in adults with decreased spontaneous bowel movements. The drug has been evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial (CTR20210918) in China. The primary efficacy endpoint of the study was the proportion of subjects achieving a complete spontaneous bowel movement within 24 hours after the first dose. As a traditional medicine, its therapeutic effect is based on Uygur medical principles, likely involving the stimulation of gastrointestinal motility through a combination of botanical ingredients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wenwei A Yayranji Pian.